Iovance Biotherapeutics said it ended the first quarter of 2026 with about $319 million in cash, a balance the company says can fund operations into 2028.
Revenue guidance for the June quarter was set at $86 million to $88 million, while full-year 2026 revenue guidance was $350 million to $370 million. The company also pointed to year-over-year quarterly revenue growth of roughly 45%.
Commercial reach continued to expand. Iovance said it had more than 90 authorized treatment centers as of May 7, 2026, including centers in final stages of readiness or soon to be authorized, and more than 1,500 patients had been treated with commercial and clinical TIL products across the U.S., Canada and Australia.
The company said its manufacturing network supports capacity for up to 5,000 patients a year across North America, Europe and Asia-Pacific.
Amtagvi’s commercial footprint in melanoma was paired with broader market access data: more than 75% of patients were covered by private payers, and financial clearance typically took about three weeks. The company said the patient journey from primary oncologist to return visit averaged about 31 days.
Clinical data highlighted in the presentation showed a 5-year overall survival rate of 19.7%, a median duration of response of 36.5 months, and an overall response rate of 31.4% in previously treated advanced melanoma, based on a pooled analysis of 153 heavily pre-treated patients. In real-world use, the response rate was reported at 52% among 23 patients, compared with 44% in 41 patients overall and 33% in 18 patients with three or more prior lines of therapy.
The company also said its addressable melanoma population included about 8.5 thousand patients in the U.S. and 22 thousand outside the U.S., with more than 50% of patients on first-line standard of care progressing within 12 months. The market has reacted to these announcements by moving the company's shares 8.56% to a price of $4.31. Check out the company's full 8-K submission here.
